サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1427912

ムコ多糖症治療の世界市場レポート 2024

Mucopolysaccharidosis Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ムコ多糖症治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ムコ多糖症治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.5%の年間複合成長率（CAGR）で31億9,000万米ドルに成長すると予想されます。予測期間で予想される成長は、遺伝子編集の大幅な進歩、サポートの強化による規制変更、患者アクセスを改善するための取り組み、新しい治療法の出現、精密医療アプローチの適用など、さまざまな要因によるものと考えられます。予測期間中に予想される主な動向には、介護者支援プログラムの実施、症状管理への重点の集中、教育および訓練の取り組み、治療への世界のアクセスの拡大、バイオマーカー開発の顕著な進歩などが含まれます。

ムコ多糖症治療市場で予想される成長は、さまざまな形態のムコ多糖症の有病率の増加によって促進されると予想されます。このグループの疾患には、消化に必要な特定の酵素の欠乏により、複合炭水化物であるムコ多糖が身体組織に蓄積することが含まれます。ムコ多糖症（MPS）治療は、体内のグリコサミノグリカン（GAG）形成を減らし、症状を管理し、さまざまな治療アプローチを通じて合併症を回避することにより、病気の進行を予防する上で重要な役割を果たします。 2021年2月の国立医学図書館の報告書で証明されているように、MPS IおよびMPS VIの出生率は出生10万人あたり3.62人と報告されています。 MPS IIIは全症例の11%を占め、計算上の割合は出生100,000人あたり1.8人でした。このさまざまな形態のムコ多糖症の有病率の拡大は、ムコ多糖症治療市場の重要な推進力になると予想されます。

ヘルスケア支出の増加は、ムコ多糖症治療市場の拡大に貢献しています。特定の地域または国のヘルスケア部門に割り当てられる財源の総額を指すヘルスケア支出は増加傾向にあります。この支出の増加はムコ多糖症（MPS）の治療に向けられ、専門的な治療法、調査への取り組み、医療インフラの強化へのアクセスの改善が促進されます。たとえば、2023年3月の米国医師会の報告書によると、米国の医療支出は2021年に2.7%増加し、4兆3,000億米ドル、つまり1人当たり1万2,914米ドルに達しました。このヘルスケア支出の増加傾向は、ムコ多糖症治療市場のさらなる成長を促進し、最終的にはこの稀な遺伝性疾患の影響を受ける個人の管理と転帰を強化すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のムコ多糖症治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 酵素補充療法
  • 幹細胞療法
  • 世界のムコ多糖症治療市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ムコ多糖症-I
  • ムコ多糖症-II
  • ムコ多糖症-IV
  • ムコ多糖症-VI
  • その他の疾患
  • 世界のムコ多糖症治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 静脈内
  • 脳室内
  • 世界のムコ多糖症治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のムコ多糖症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のムコ多糖症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ムコ多糖症治療市場の競合情勢
  • ムコ多糖症治療市場企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • Roche Holding AG
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 その他の大手および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • BioMarin Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals
  • Green Cross Corporation
  • Sarepta Therapeutics Inc.
  • Esteve SA
  • JCR Pharmaceuticals Co. Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • RegenxBio Inc.
  • Sangamo Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13756

The treatment of Mucopolysaccharidosis (MPS) involves addressing hereditary illnesses characterized by the body's inability to break down glycosaminoglycan (long sugar chains) due to the deficiency or malfunction of specific enzymes, often lysosomal enzymes.

Two primary types of treatments for mucopolysaccharidosis are enzyme replacement therapy and stem cell therapy. Enzyme replacement therapy is a medical intervention designed for patients with chronic diseases resulting from enzyme deficiency or dysfunction. This approach involves providing replacement enzymes to individuals affected by various forms of mucopolysaccharidosis, including types I, II, IV, VI, and others. These replacement enzymes are administered through intravenous and intracerebroventricular routes of administration. The therapy is implemented in diverse healthcare settings, including hospitals, specialty clinics, and other medical facilities.

The mucopolysaccharidosis treatment market research report is one of a series of new reports from The Business Research Company that provides mucopolysaccharidosis treatment market statistics, including mucopolysaccharidosis treatment industry global market size, regional shares, competitors with a mucopolysaccharidosis treatment market share, detailed mucopolysaccharidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mucopolysaccharidosis treatment industry. This mucopolysaccharidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.2 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth observed in the historic period can be ascribed to several factors, including the widespread adoption of enzyme replacement therapy (ERT), advancements in diagnostic tools, increased advocacy and awareness initiatives, ongoing developments in gene therapy, and the continuous enhancement of healthcare infrastructure.

The mucopolysaccharidosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to various factors, including significant advancements in gene editing, regulatory changes with increased support, initiatives to improve patient access, the emergence of new therapeutic modalities, and the application of precision medicine approaches. Key trends expected in the forecast period encompass the implementation of caregiver support programs, a heightened focus on symptom management, educational and training initiatives, expanded global access to treatments, and notable progress in the development of biomarkers.

The anticipated growth in the mucopolysaccharidosis treatment market is expected to be propelled by the increasing prevalence of various forms of mucopolysaccharidosis. This group of disorders involves the accumulation of mucopolysaccharides, a complex carbohydrate, in bodily tissues due to a deficiency of specific enzymes required for digestion. Mucopolysaccharidosis (MPS) therapy plays a crucial role in preventing disease progression by reducing glycosaminoglycan (GAG) formation in the body, managing symptoms, and averting complications through diverse therapeutic approaches. As evidenced by a report from the National Library of Medicine in February 2021, the prevalence of MPS I and MPS VI births was reported at 3.62 per 100,000 live births. MPS III constituted 11% of all cases, with a calculated rate of 1.8 per 100,000 live births. This escalating prevalence across various forms of mucopolysaccharidosis is expected to be a significant driver for the mucopolysaccharidosis treatment market.

The growth in healthcare spending is contributing to the expansion of the mucopolysaccharidosis treatment market. Healthcare spending, referring to the total financial resources allocated to the healthcare sector within a specific region or country, is on the rise. This increased spending is directed towards mucopolysaccharidosis (MPS) treatment, facilitating improved access to specialized therapies, research initiatives, and enhanced medical infrastructure. For instance, according to a report by the American Medical Association in March 2023, health spending in the United States increased by 2.7% in 2021, reaching $4.3 trillion, or $12,914 per capita. This upward trend in healthcare spending is expected to drive further growth in the mucopolysaccharidosis treatment market, ultimately enhancing the management and outcomes for individuals affected by this rare genetic disorder.

Product innovation emerges as a pivotal trend gaining momentum in the mucopolysaccharidosis treatment market, with major companies actively pursuing new product developments to maintain their competitive edge. Illustrating this trend is the approval of IZCARGO (Pabinafusp Alfa) by JCR Pharmaceuticals in March 2021 for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, in Japan. This milestone marked the first-ever enzyme replacement therapy (ERT) for MPS II capable of crossing the blood-brain barrier through intravenous administration, leveraging JCR's proprietary J-Brain Cargo Technology. This innovative product, a recombinant iduronate-2-sulfatase enzyme replacement therapy, holds significant promise for individuals with lysosomal storage disorders such as MPS II.

Major players in the mucopolysaccharidosis treatment market are directing their focus towards cell therapies as a promising avenue for addressing rare genetic disorders. A case in point is ISP-001, developed by Immusoft, a US-based biotechnology company. ISP-001 represents a pioneering approach utilizing cell therapy to administer gene-encoded medicine, targeting the root cause of Mucopolysaccharidosis I (MPS I). In September 2022, Immusoft achieved a significant milestone with the FDA clearance of its Investigational New Drug (IND) application for ISP-001, marking a groundbreaking advancement in engineered B cell therapy for MPS I treatment.

In October 2021, Takeda Pharmaceutical Company, a Japan-based pharmaceutical giant, entered into a partnership with JCR Pharmaceutical. This collaboration aims to facilitate the development and commercialization of JR-141, an experimental antibody fusion protein designed to target the human transferrin receptor for treating Hunter syndrome, a subtype of mucopolysaccharidosis. This strategic alliance underscores a concerted effort to expedite the delivery of innovative treatments to patients and enhance their quality of life.

Major companies operating in the mucopolysaccharidosis treatment market report are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Sarepta Therapeutics Inc., Esteve SA, JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Eidos Therapeutics Inc., Neurogene Inc., Immusoft Corporation, Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., Rimedion Inc., Eloxx Pharmaceuticals Inc., iBio Inc., Abeona Therapeutics Inc.

North America was the largest region in the mucopolysaccharidosis treatment market in 2023. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mucopolysaccharidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mucopolysaccharides treatment market includes revenues earned by entities by providing medication services such as enzyme replacement therapy, stem cell transplantation, gene therapy, substrate reduction therapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mucopolysaccharidosis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mucopolysaccharidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mucopolysaccharidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mucopolysaccharidosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Treatment: Enzyme Replacement Therapy; Stem Cell Therapy
  • 2) By Disease: Mucopolysaccharidosis- I; Mucopolysaccharidosis- II; Mucopolysaccharidosis-IV; Mucopolysaccharidosis-VI; Other Diseases
  • 3) By Route of Administration: Intravenous; Intracerebroventricular
  • 4) By End-User: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mucopolysaccharidosis Treatment Market Characteristics

3. Mucopolysaccharidosis Treatment Market Trends And Strategies

4. Mucopolysaccharidosis Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Mucopolysaccharidosis Treatment Market Size and Growth

  • 5.1. Global Mucopolysaccharidosis Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Mucopolysaccharidosis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Mucopolysaccharidosis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Mucopolysaccharidosis Treatment Market Segmentation

  • 6.1. Global Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • 6.2. Global Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Mucopolysaccharidosis- I
  • Mucopolysaccharidosis- II
  • Mucopolysaccharidosis-IV
  • Mucopolysaccharidosis-VI
  • Other Diseases
  • 6.3. Global Mucopolysaccharidosis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intravenous
  • Intracerebroventricular
  • 6.4. Global Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users

7. Mucopolysaccharidosis Treatment Market Regional And Country Analysis

  • 7.1. Global Mucopolysaccharidosis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Mucopolysaccharidosis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Mucopolysaccharidosis Treatment Market

  • 8.1. Asia-Pacific Mucopolysaccharidosis Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Mucopolysaccharidosis Treatment Market

  • 9.1. China Mucopolysaccharidosis Treatment Market Overview
  • 9.2. China Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Mucopolysaccharidosis Treatment Market

  • 10.1. India Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Mucopolysaccharidosis Treatment Market

  • 11.1. Japan Mucopolysaccharidosis Treatment Market Overview
  • 11.2. Japan Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Mucopolysaccharidosis Treatment Market

  • 12.1. Australia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Mucopolysaccharidosis Treatment Market

  • 13.1. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Mucopolysaccharidosis Treatment Market

  • 14.1. South Korea Mucopolysaccharidosis Treatment Market Overview
  • 14.2. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Mucopolysaccharidosis Treatment Market

  • 15.1. Western Europe Mucopolysaccharidosis Treatment Market Overview
  • 15.2. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Mucopolysaccharidosis Treatment Market

  • 16.1. UK Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Mucopolysaccharidosis Treatment Market

  • 17.1. Germany Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Mucopolysaccharidosis Treatment Market

  • 18.1. France Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Mucopolysaccharidosis Treatment Market

  • 19.1. Italy Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Mucopolysaccharidosis Treatment Market

  • 20.1. Spain Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Mucopolysaccharidosis Treatment Market

  • 21.1. Eastern Europe Mucopolysaccharidosis Treatment Market Overview
  • 21.2. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Mucopolysaccharidosis Treatment Market

  • 22.1. Russia Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Mucopolysaccharidosis Treatment Market

  • 23.1. North America Mucopolysaccharidosis Treatment Market Overview
  • 23.2. North America Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Mucopolysaccharidosis Treatment Market

  • 24.1. USA Mucopolysaccharidosis Treatment Market Overview
  • 24.2. USA Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Mucopolysaccharidosis Treatment Market

  • 25.1. Canada Mucopolysaccharidosis Treatment Market Overview
  • 25.2. Canada Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Mucopolysaccharidosis Treatment Market

  • 26.1. South America Mucopolysaccharidosis Treatment Market Overview
  • 26.2. South America Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Mucopolysaccharidosis Treatment Market

  • 27.1. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Mucopolysaccharidosis Treatment Market

  • 28.1. Middle East Mucopolysaccharidosis Treatment Market Overview
  • 28.2. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Mucopolysaccharidosis Treatment Market

  • 29.1. Africa Mucopolysaccharidosis Treatment Market Overview
  • 29.2. Africa Mucopolysaccharidosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Mucopolysaccharidosis Treatment Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Mucopolysaccharidosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Mucopolysaccharidosis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Mucopolysaccharidosis Treatment Market Competitive Landscape
  • 30.2. Mucopolysaccharidosis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Roche Holding AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Mucopolysaccharidosis Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A.
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. GlaxoSmithKline plc
  • 31.5. Takeda Pharmaceutical Co. Ltd.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. BioMarin Pharmaceuticals Inc.
  • 31.8. Mallinckrodt Pharmaceuticals
  • 31.9. Green Cross Corporation
  • 31.10. Sarepta Therapeutics Inc.
  • 31.11. Esteve SA
  • 31.12. JCR Pharmaceuticals Co. Ltd.
  • 31.13. Ultragenyx Pharmaceutical Inc.
  • 31.14. RegenxBio Inc.
  • 31.15. Sangamo Therapeutics Inc.

32. Global Mucopolysaccharidosis Treatment Market Competitive Benchmarking

33. Global Mucopolysaccharidosis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Mucopolysaccharidosis Treatment Market

35. Mucopolysaccharidosis Treatment Market Future Outlook and Potential Analysis

  • 35.1 Mucopolysaccharidosis Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Mucopolysaccharidosis Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Mucopolysaccharidosis Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer